LXEO
Lexeo Therapeutics, Inc. Common Stock
NASDAQ · USHealthcareBiotechnology
$4.55-2.99%
Price as of Jul 20, 2026
LXEO financials
Lexeo Therapeutics, Inc. Common Stock financial statements
Annual and quarterly income statement, balance sheet and cash-flow history. On small screens, start with four periods and expand the table when needed.
| Metric | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|
| Income statement | ||||
| Revenue | $0.00 | $0.00 | $0.00 | $654.0K |
| Cost of revenue | $0.00 | $0.00 | $0.00 | $0.00 |
| Gross profit | $0.00 | $0.00 | $0.00 | $654.0K |
| Operating expenses | $109.3M | $105.8M | $68.5M | $61.2M |
| Operating income | -$109.3M | -$105.8M | -$68.5M | -$60.5M |
| Net income | -$100.0M | -$98.3M | -$66.4M | -$59.3M |
| EBITDA | -$97.7M | -$96.2M | -$64.3M | -$58.0M |
| Basic EPS | $-1.86 | $-3.09 | $-2.49 | $-2.36 |
| Diluted EPS | $-1.86 | $-3.09 | $-2.49 | $-2.40 |
| Balance sheet | ||||
| Cash & equivalents | $63.0M | $35.0M | $121.5M | $77.3M |
| Total assets | $268.7M | $146.9M | $139.8M | $97.1M |
| Total liabilities | $22.0M | $30.1M | $26.3M | $210.0M |
| Stockholders’ equity | $246.7M | $116.8M | $113.5M | -$113.0M |
| Total debt | $7.9M | $9.9M | $11.6M | $13.5M |
| Net debt | -$55.1M | -$25.1M | -$109.8M | -$63.9M |
| Cash flow | ||||
| Operating cash flow | -$98.6M | -$81.2M | -$59.5M | -$54.6M |
| Capital expenditure | -$397.0K | -$481.0K | -$165.0K | -$901.0K |
| Free cash flow | -$99.0M | -$81.6M | -$59.7M | -$55.5M |
| Dividends paid | $0.00 | $0.00 | $0.00 | $0.00 |
| Share repurchases | $0.00 | -$17.0K | $0.00 | $0.00 |